These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34077449)

  • 1. A novel method of screening combinations of angiostatics identifies bevacizumab and temsirolimus as synergistic inhibitors of glioma-induced angiogenesis.
    Dorrell MI; Kast-Woelbern HR; Botts RT; Bravo SA; Tremblay JR; Giles S; Wada JF; Alexander M; Garcia E; Villegas G; Booth CB; Purington KJ; Everett HM; Siles EN; Wheelock M; Silva JA; Fortin BM; Lowey CA; Hale AL; Kurz TL; Rusing JC; Goral DM; Thompson P; Johnson AM; Elson DJ; Tadros R; Gillette CE; Coopwood C; Rausch AL; Snowbarger JM
    PLoS One; 2021; 16(6):e0252233. PubMed ID: 34077449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
    Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
    J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tricin, 4',5,7-trihydroxy-3',5'-dimethoxyflavone, exhibits potent antiangiogenic activity in vitro.
    Han JM; Kwon HJ; Jung HJ
    Int J Oncol; 2016 Oct; 49(4):1497-504. PubMed ID: 27498749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
    Winkler F; Osswald M; Wick W
    Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization.
    Weiss A; van Beijnum JR; Bonvin D; Jichlinski P; Dyson PJ; Griffioen AW; Nowak-Sliwinska P
    J Cell Mol Med; 2014 Mar; 18(3):480-91. PubMed ID: 24450440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis in human brain tumors: screening of drug response through a patient-specific cell platform for personalized therapy.
    Guarnaccia L; Navone SE; Trombetta E; Cordiglieri C; Cherubini A; Crisà FM; Rampini P; Miozzo M; Fontana L; Caroli M; Locatelli M; Riboni L; Campanella R; Marfia G
    Sci Rep; 2018 Jun; 8(1):8748. PubMed ID: 29884885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane.
    Nap AW; Dunselman GA; Griffioen AW; Mayo KH; Evers JL; Groothuis PG
    Fertil Steril; 2005 Mar; 83(3):793-5. PubMed ID: 15749522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer.
    Weiss A; Ding X; van Beijnum JR; Wong I; Wong TJ; Berndsen RH; Dormond O; Dallinga M; Shen L; Schlingemann RO; Pili R; Ho CM; Dyson PJ; van den Bergh H; Griffioen AW; Nowak-Sliwinska P
    Angiogenesis; 2015 Jul; 18(3):233-44. PubMed ID: 25824484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel four-step system for screening angiogenesis inhibitors.
    Zhou Q; Qi CL; Li Y; He XD; Li JC; Zhang QQ; Tian L; Zhang M; Han Z; Wang H; Yang X; Wang LJ
    Mol Med Rep; 2013 Dec; 8(6):1734-40. PubMed ID: 24068303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
    Mathieu V; De Nève N; Le Mercier M; Dewelle J; Gaussin JF; Dehoux M; Kiss R; Lefranc F
    Neoplasia; 2008 Dec; 10(12):1383-92. PubMed ID: 19048117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting neovascularization and respiration of tumor grafts grown on chick embryo chorioallantoic membranes.
    Ademi H; Shinde DA; Gassmann M; Gerst D; Chaachouay H; Vogel J; Gorr TA
    PLoS One; 2021; 16(5):e0251765. PubMed ID: 33999935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model.
    Ramezani S; Vousooghi N; Ramezani Kapourchali F; Yousefzadeh-Chabok S; Reihanian Z; Alizadeh AM; Khodayari S; Khodayari H
    Life Sci; 2019 Dec; 239():116880. PubMed ID: 31678282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
    Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
    Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
    Fleuren ED; Versleijen-Jonkers YM; Roeffen MH; Franssen GM; Flucke UE; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
    Int J Cancer; 2014 Dec; 135(12):2770-82. PubMed ID: 24771207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
    Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
    Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in high-grade gliomas: past, present, and future.
    Curry RC; Dahiya S; Alva Venur V; Raizer JJ; Ahluwalia MS
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):387-97. PubMed ID: 25797685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.